Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Adjuvant Therapy in High-Risk HCC After LDLT
NCT06327269Phase 1Recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Apr 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Recurrence-free survival with adjuvant therapy at 2 years. Started Apr 2021; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06327269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06327269.